The Quality Lowdown: Risk And Opportunity
Executive Summary
Recent developments confirm the laser focus of the US FDA and the pharmaceutical industry on managing quality risks such as potentially carcinogenic impurities, product mix-ups and microbial contamination. But they also underscored opportunities like global regulatory harmonization, assay development and responses to negative pre-approval inspections.
You may also be interested in...
FDA Gets Final With Guidance On Recall Public Warnings, Notifications
There may be fewer recalls, but they are getting more publicity, in part because of FDA warnings that one recalcitrant firm said “decimated” sales.
Recall-Related Public Warnings Get Final US FDA Guidance
There may be fewer recalls, but they are getting more publicity, in part because of FDA warnings that one recalcitrant firm said “decimated” sales.
US FDA Warning Letter Hits Huahai For Failure To Prevent Valsartan Contamination
Zhejiang Huahai should have realized its valsartan API was tainted by the probable carcinogen NDMA, FDA says in warning letter, despite earlier statement from agency leadership to the contrary.